Enovis Corporation entered into a binding offer to acquire eCential Robotics SAS, a developer of surgical robotics and enabling technologies, for an enterprise value of approximately €155 million. The transaction involves upfront cash consideration of roughly €176 million to shareholders, with potential additional contingent payments of up to €35 million upon milestone achievement. Enovis plans to fund the deal using existing cash and its revolving credit facility, expecting closure by year-end 2026 subject to regulatory approvals. The acquisition aims to integrate robotic automation into Enovis' ASTRA platform, though it is expected to cause a 100 basis point headwind to adjusted EBITDA margins in 2027 due to deal-related dilution. Enovis Corporation operates as a global medical technology innovator focused on solutions that enhance patient outcomes and restore motion.

Enovis Corporation reported financial results for the second quarter ended July 3, 2026, announcing net sales of $583 million, a 3% increase on a reported basis and 5% organic growth compared to the prior year. The company posted a net loss of $1 million, or $0.02 per diluted share, alongside adjusted EBITDA of $104 million, representing a 17.9% margin. Reconstructive sales grew 8% reported (6% organic), while Prevention & Recovery sales declined 1% reported but grew 3% organically. Enovis reaffirmed its full-year 2026 guidance, projecting revenue between $2.31 billion and $2.37 billion, adjusted EBITDA of $425 million to $435 million, and adjusted EPS of $3.52 to $3.73. The company operates in the medical technology industry, developing solutions for patient recovery and reconstructive surgery.